| "Streptococcus productus" Prevot 1941| ATCC 27340| Blautia producta| Blautia producta (Prevot 1941) Liu et al. 2008| CCUG 10976| CCUG 9990| DSM 2950| JCM 1471| Peptostreptococcus productus| Peptostreptococcus productus (Prevot 1941) Smith 1957 (Approved Lists 1980)| Ruminococcus productus| Ruminococcus productus (Prevot 1941) Ezaki et al. 1994| Streptococcus productus
Short-chain fatty acid production: Blautia species, including Blautia producta, are known for their ability to ferment dietary fibers and produce short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, as metabolic byproducts. SCFAs play important roles in maintaining gut health by providing energy to intestinal epithelial cells, regulating immune function, and modulating inflammation. Therefore, the presence of Blautia producta in the gut microbiota may contribute to overall gut homeostasis and health.
Metabolic disorders: Changes in the composition and function of the gut microbiota, including alterations in Blautia abundance, have been associated with various metabolic disorders, such as obesity, type 2 diabetes, and metabolic syndrome. While the exact role of Blautia producta in metabolic health is not fully understood, its presence in the gut microbiota may influence host metabolism through SCFA production, nutrient metabolism, and interactions with other microbial taxa.
Gut-brain axis: Emerging research suggests that the gut microbiota, including bacteria like Blautia producta, may play a role in the gut-brain axis, a bidirectional communication system between the gut and the brain. Alterations in the gut microbiota composition have been linked to neurological and psychiatric conditions, such as depression, anxiety, and autism spectrum disorders. While the specific impact of Blautia producta on neurological health is unclear, its presence in the gut microbiota may influence neuroimmune signaling, neurotransmitter production, and brain function.
Inflammatory bowel disease (IBD): Changes in the gut microbiota composition, including alterations in Blautia abundance, have been observed in individuals with inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. While the role of Blautia producta specifically in IBD pathogenesis is not well-defined, its presence in the gut microbiota may contribute to intestinal inflammation, mucosal barrier function, and immune dysregulation.
Dietary influences: The abundance of Blautia species, including Blautia producta, in the gut microbiota can be influenced by dietary factors, particularly fiber intake. Diets rich in fermentable fibers promote the growth of Blautia and other fiber-degrading bacteria, leading to increased SCFA production and potential health benefits. Conversely, diets low in fiber and high in processed foods may reduce Blautia abundance and alter gut microbiota composition, potentially contributing to gastrointestinal and metabolic disorders.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 2.38 | 0 | 0 | 10 | 38800 | 0 | 12548 | 1990.7 | 707 | 5386.6 | 0 | 3044 | 0 %ile | 100 %ile |
biomesight | 71.21 | 0 | 570 | 30 | 2330 | 0 | 29585 | 3001.5 | 330 | 13562.9 | 0 | 2570 | 9.1 %ile | 90 %ile |
thorne | 100 | 392 | 4755 | 0 | 2827 | 1226.9 | 1013 | 816.5 | 561 | 1697 | 0 %ile | 100 %ile | ||
thryve | 96.66 | 69 | 2275 | 165 | 2099 | 0 | 7459 | 1544.2 | 610 | 3017.6 | 0 | 2288 | 10.8 %ile | 90.6 %ile |
ubiome | 9.51 | 0 | 0 | 24 | 9900 | 0 | 3098 | 493.3 | 137 | 1329 | 3 | 389 | 0 %ile | 100 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 0 | 1.34 | 0 | 0.0001 |
XenoGene | 10000 | 60000 | 1 | 6 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
Biomesight | 75.523 % | 0.285 % | 1.271 % | 2237.0 | 2962 |
BiomeSightRdp | 25.806 % | 0.006 % | 0.003 % | 8.0 | 31 |
bugspeak | 100 % | 0.007 % | % | 1.0 | 1 |
CerbaLab | 100 % | 0.14 % | 0.051 % | 3.0 | 3 |
CosmosId | 68.75 % | 0.296 % | 0.833 % | 22.0 | 32 |
custom | 16.393 % | 0.148 % | 0.06 % | 10.0 | 61 |
es-xenogene | 96.552 % | 0.193 % | 0.113 % | 28.0 | 29 |
Medivere | 14.286 % | 0.005 % | % | 1.0 | 7 |
Microba | 10.714 % | 0.117 % | 0.098 % | 3.0 | 28 |
Microba1 | 100 % | 0.09 % | % | 1.0 | 1 |
Thorne | 87.255 % | 0.141 % | 0.247 % | 89.0 | 102 |
Thryve | 97.192 % | 0.144 % | 0.271 % | 1350.0 | 1389 |
uBiome | 9.47 % | 0.049 % | 0.133 % | 75.0 | 792 |
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.